Oxford Biomedica PLC - gene and cell therapy company - Says UK Prime Minister Boris Johnson has formally opened its new 84,000 square feet manufacturing facility Oxbox based in Oxford, UK. Oxbox was originally built to solely service thecompany's growing demand for lentiviral vectors in the fast growing cell and gene therapy market where it is a leading global specialist working with multiple partners including Novartis AG, BMS and Sanofi SA.
Current stock price: 922.00 pence
Year-to-date change: down 8.2%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)